Biogen Inc (IDP.HM)
| Previous close | 238.50 |
| Open | 244.20 |
| Bid | 250.25 x 0 |
| Ask | 251.85 x 0 |
| Day's range | 244.20 - 244.20 |
| 52-week range | 178.38 - 307.50 |
| Volume | |
| Avg. volume | 2 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 01 May 2023 - 05 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Yahoo Finance Video
Leqembi: Medicare coverage needs ‘a convincing set of evidence’ for FDA approval, analyst says
William Blair Biotech Equity Research Analyst Myles Minter joins Yahoo Finance Live to discuss his Outperform rating on Biogen stock, Biogen’s Alzheimer and depression treatment drugs, full-year guidance, profit growth, cost-cutting efforts, and the outlook for the company.
- Business Wire
Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
CAMBRIDGE, Mass., February 06, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an investigational drug being evaluated as a 14-day, rapid-acting, once-daily, oral treatment in adults with MDD and PPD. The application has been granted priority revie
- Yahoo Finance Video
FDA approves Biogen-Eisai Alzheimer’s drug, China in talks to make Pfizer Paxlovid generic
Yahoo Finance health care reporter Anjalee Khemlani highlights the progress on Biogen-Eisai's collaborative Alzheimer's treatment drug and China's plans to distribute Pfizer's Paxlovid pill.
